Combined Approaches Leading to Synergistic Therapeutic Effects in Spinal Cord Injury: State of the Art.

cell therapy locomotor load neuromodulation spinal cord injury

Journal

Frontiers in bioscience (Landmark edition)
ISSN: 2768-6698
Titre abrégé: Front Biosci (Landmark Ed)
Pays: Singapore
ID NLM: 101612996

Informations de publication

Date de publication:
28 12 2022
Historique:
received: 19 07 2022
revised: 25 08 2022
accepted: 30 08 2022
entrez: 10 1 2023
pubmed: 11 1 2023
medline: 12 1 2023
Statut: ppublish

Résumé

Cell-based regenerative medicine approaches and motor rehabilitation are currently being used to overcome the consequences of spinal cord injury (SCI). However, their success in preclinical studies does not always translate into successful implementation in clinical practice. Recent work suggests that modern neuromodulation approaches hold great therapeutic promise. Despite these advances, the complete resolution of functional deficits caused by SCI is impossible, especially in cases of severe injury. Therefore, combined approaches based on cell transplantation and neuromodulation are needed to enhance the neuroregenerative effect. The additional inclusion of a dosed locomotor load in the overall therapeutic plan and against a background of combined approaches can have a significant supportive effect. The aim of this review is to evaluate studies that use combinations of different approaches, thereby advancing our current understanding of the mechanisms that underlie their therapeutic effect. This review will consider mostly the effects and limitations of regenerative approaches, as well as the effects of locomotor load and neuromodulation on molecular and cellular changes in the spinal cord.

Identifiants

pubmed: 36624937
pii: S2768-6701(22)00629-3
doi: 10.31083/j.fbl2712334
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

334

Informations de copyright

© 2022 The Author(s). Published by IMR Press.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

Eldar Davletshin (E)

OpenLab Gene and Cell Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, 420021 Kazan, Russia.

Davran Sabirov (D)

OpenLab Gene and Cell Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, 420021 Kazan, Russia.

Albert Rizvanov (A)

OpenLab Gene and Cell Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, 420021 Kazan, Russia.

Yana Mukhamedshina (Y)

OpenLab Gene and Cell Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, 420021 Kazan, Russia.
Department of Histology, Cytology and Embryology, Kazan State Medical University, 420008 Kazan, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH